OBJECTIVE The aim of this study was to investigate the efficacy and safety of continuous subcutaneous insulin infusion (CSII) regarding glycaemic control and quality of life in patients with type 1 diabetes mellitus (T1DM), who were previously treated with multiple daily injections (MDI). PATIENTS AND METHODS 140 patients with T1DM [mean age 33.7 ± 22.1 years; 54 males, 76 females, 10 children; duration of diabetes 19.1 ± 8.4 years; total daily insulin usage while on MDI (IU/day) 57.86 ± 15.32; HbA1c at the beginning of CSII treatment 8.67 ± 1.54%] were included in the study. HbA1c, glucose levels, BMI, severe hypoglycemic and diabetic ketoacidosis (DKA) episodes were recorded and compared to the data prior to CSII introduction. The evaluation of the quality of life was assessed with a self-questionnaire adjusted from the SF-12 and diabetes quality of life (DQoL) questionnaires. RESULTS HbA1c was reduced from 8.67 ± 1.54 to 6.85 ± 0.52% (p < 0.001). This reduction was independent of age, gender, body mass index (BMI) and diabetes duration. Daily insulin requirements were lower at the end of the follow-up (36.40 ± 12.20 IU/day) compared with the needs during enrolment (57.86 ± 15.32 IU/day) (p < 0.001). BMI presented no significant alterations. Ten (10) severe hypoglycemic episodes were recorded but the overall rate was decreased by 71.5% (p < 0.001). Only 3 cases of ketoacidosis were recorded. Quality of life parameters were remarkably improved. CONCLUSIONS This study provided evidence that CSII treatment was superior to MDI for patients with T1DM in Greece. CSII offered a safe, effective alternative to MDI, while improving glycaemic control, side-effects and quality of life.

中文翻译：

---

希腊使用的胰岛素泵：140例1型糖尿病患者的疗效和安全性数据。

目的本研究的目的是研究连续皮下注射胰岛素（CSII）在1型糖尿病（T1DM）患者中的血糖控制和生活质量方面的有效性和安全性，这些患者先前曾多次每日注射（MDI） 。患者与方法140例T1DM患者[平均年龄33.7±22.1岁；男54名，女76名，子女10名；糖尿病持续时间19.1±8.4年；每天服用MDI的每日胰岛素总使用量（IU /天）57.86±15.32; CSII治疗开始时的HbA1c为8.67±1.54％]。记录HbA1c，血糖水平，BMI，严重的低血糖和糖尿病性酮症酸中毒（DKA）发作，并将其与CSII引入前的数据进行比较。生活质量的评估是根据SF-12和糖尿病生活质量（DQoL）调查表进行的自我问卷调查而得出的。结果HbA1c从8.67±1.54降低至6.85±0.52％（p <0.001）。这种减少与年龄，性别，体重指数（BMI）和糖尿病病程无关。与入组时的需求量（57.86±15.32 IU /天）相比，随访结束时的每日胰岛素需求量较低（36.40±12.20 IU /天）（p <0.001）。体重指数没有明显改变。记录到十（10）次严重的降血糖事件，但总发生率降低了71.5％（p <0.001）。仅记录了3例酮症酸中毒病例。生活质量参数明显提高。结论这项研究提供的证据表明，对于希腊的T1DM患者，CSII治疗优于MDI。